Logo image of LPTX

LEAP THERAPEUTICS INC (LPTX) Stock Fundamental Analysis

NASDAQ:LPTX - Nasdaq - US52187K2006 - Common Stock - Currency: USD

0.5193  -0.05 (-9.15%)

After market: 0.523 +0 (+0.71%)

Fundamental Rating

2

LPTX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. LPTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. LPTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

LPTX had negative earnings in the past year.
LPTX had a negative operating cash flow in the past year.
LPTX had negative earnings in each of the past 5 years.
LPTX had a negative operating cash flow in each of the past 5 years.
LPTX Yearly Net Income VS EBIT VS OCF VS FCFLPTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

LPTX's Return On Assets of -99.66% is on the low side compared to the rest of the industry. LPTX is outperformed by 75.93% of its industry peers.
LPTX has a worse Return On Equity (-132.42%) than 61.95% of its industry peers.
Industry RankSector Rank
ROA -99.66%
ROE -132.42%
ROIC N/A
ROA(3y)-74.59%
ROA(5y)-148.47%
ROE(3y)-88.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LPTX Yearly ROA, ROE, ROICLPTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2K -2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for LPTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LPTX Yearly Profit, Operating, Gross MarginsLPTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -500 -1K -1.5K -2K -2.5K

More info and screens

6

2. Health

2.1 Basic Checks

LPTX has more shares outstanding than it did 1 year ago.
LPTX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for LPTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LPTX Yearly Shares OutstandingLPTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
LPTX Yearly Total Debt VS Total AssetsLPTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

LPTX has an Altman-Z score of -11.52. This is a bad value and indicates that LPTX is not financially healthy and even has some risk of bankruptcy.
LPTX's Altman-Z score of -11.52 is on the low side compared to the rest of the industry. LPTX is outperformed by 77.88% of its industry peers.
LPTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.52
ROIC/WACCN/A
WACCN/A
LPTX Yearly LT Debt VS Equity VS FCFLPTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

A Current Ratio of 3.97 indicates that LPTX has no problem at all paying its short term obligations.
LPTX's Current ratio of 3.97 is in line compared to the rest of the industry. LPTX outperforms 45.84% of its industry peers.
A Quick Ratio of 3.97 indicates that LPTX has no problem at all paying its short term obligations.
LPTX has a Quick ratio of 3.97. This is comparable to the rest of the industry: LPTX outperforms 47.79% of its industry peers.
Industry RankSector Rank
Current Ratio 3.97
Quick Ratio 3.97
LPTX Yearly Current Assets VS Current LiabilitesLPTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 65.66% over the past year.
EPS 1Y (TTM)65.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.73%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

LPTX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.21% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y63.16%
EPS Next 2Y32.14%
EPS Next 3Y20.81%
EPS Next 5Y12.21%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LPTX Yearly Revenue VS EstimatesLPTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M 500M
LPTX Yearly EPS VS EstimatesLPTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -5 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LPTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LPTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LPTX Price Earnings VS Forward Price EarningsLPTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LPTX Per share dataLPTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as LPTX's earnings are expected to grow with 20.81% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.14%
EPS Next 3Y20.81%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LPTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LEAP THERAPEUTICS INC

NASDAQ:LPTX (1/30/2025, 5:30:09 PM)

After market: 0.523 +0 (+0.71%)

0.5193

-0.05 (-9.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/bmo
Earnings (Next)N/A N/A
Inst Owners40.12%
Inst Owner Change0.44%
Ins Owners0.25%
Ins Owner Change0%
Market Cap19.90M
Analysts84.44
Price Target11.6 (2133.78%)
Short Float %6.91%
Short Ratio6.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.21%
Min EPS beat(2)-18.56%
Max EPS beat(2)10.13%
EPS beat(4)3
Avg EPS beat(4)6.03%
Min EPS beat(4)-18.56%
Max EPS beat(4)18%
EPS beat(8)6
Avg EPS beat(8)-21.4%
EPS beat(12)8
Avg EPS beat(12)-17.33%
EPS beat(16)9
Avg EPS beat(16)-14.74%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)20.51%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.52%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.41
P/tB 0.41
EV/EBITDA N/A
EPS(TTM)-1.93
EYN/A
EPS(NY)-1.29
Fwd EYN/A
FCF(TTM)-1.44
FCFYN/A
OCF(TTM)-1.44
OCFYN/A
SpS0
BVpS1.28
TBVpS1.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -99.66%
ROE -132.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-74.59%
ROA(5y)-148.47%
ROE(3y)-88.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.97
Quick Ratio 3.97
Altman-Z -11.52
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)65.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.73%
EPS Next Y63.16%
EPS Next 2Y32.14%
EPS Next 3Y20.81%
EPS Next 5Y12.21%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-21.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-18.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-18.01%
OCF growth 3YN/A
OCF growth 5YN/A